Previous karyotyping showed a combined trisomy of chromosome 7 and 17 in sporadic and hereditary papillary renal cell tumours (RCT). A recent molecular analysis revealed a mutation in the MET tyrosine kinase (chromosome 7q31) in the germline of four out of seven families with hereditary papillary RCT (HPRCT). We have analysed germline cells as well as multiple tumours obtained from HPRCT families and sporadic cases for alteration of the MET tyrosine kinase and for allelic duplication at chromosome 7 and 17. We have detected a germ line mutation in the MET tyrosine kinase in one of the two families with HPRCTs and also found the same mutation in the germ line of one patient with clinically recognized multiple, bilateral papillary RCTs but without family history. The mutant MET allele is consequently duplicated and overexpressed in tumour cells indicating that duplication of the mutant MET allele is necessary before cells enter the tumorigenic pathway. The lack of germline mutation in two members of another HPRT family and duplication of the same parental allele of chromosome 7 in multiple tumours suggests that a germ line event other than mutation of MET tyrosine kinase is involved in the development of these tumours. Duplication of dierent alleles of chromosome 7 in sporadic and of chromosome 17 in both types of tumours excludes a germline mutation at these chromosomal sites.
Introduction
Papillary renal cell tumours (RCT) were recognized as a genetically de®ned entity among kidney cancers nearly one decade ago (Kovacs, 1989) . They are characterised by chromosomal duplications whereas all other types of renal cell tumours show LOH at speci®c genomic regions (Kovacs, 1993) . Loss of the Y chromosome and combined trisomy of chromosome 7 and 17 have been detected in small papillary adenomas of 2 mm in diameter indicating that these are the ®rst visible genetic changes (Kovacs, 1989) . The progression of such lesions into malignant papillary renal cell carcinomas (RCC) is accompanied by additional trisomies of chromosomes 3q, 8p, 12q, 16q and 20q (Kovacs et al., 1991; Palmedo et al., 1997) . Since the development of sporadic papillary RCTs is associated with multiple precursor lesions resembling nephrogenic rests , the embryonal origin of papillary RCTs was suggested (Kovacs, 1993) . It was proposed that an increased dosage of normal or mutated oncogenes, rather than inactivation of tumour suppressor genes trigger the proliferation of such embryonal rest cells (Kovacs et al., 1991) .
Recently, a rare hereditary form of papillary RCT (HPRCT) with development of multiple tumours at earlier age of onset has been identi®ed (Zbar et al., 1995) . Tumours arising in gene carriers have karyotype changes identical to those of sporadic cases (Bentz et al., 1996; Kovacs, unpublished) . Of particular importance, Bernues et al. (1995) found a partial duplication of chromosome 7q21-q35 region in a tumour obtained from a HPRCT family. The susceptibility to tumour development was linked to chromosome 7q31.1-q34 region and subsequently a mutation of MET tyrosine kinase was found in the germline of four out of seven families . The following questions arise from these ®ndings: (a) is the mutant MET allele duplicated and overexpressed in tumours from HPRCT families and (b) is the same chromosome 7 or 17 allele duplicated in multiple hereditary and sporadic papillary RCTs without germline mutation of the MET oncogene indicating another germline event?
In order to answer these questions, we have analysed multiple papillary RCTs obtained from sporadic cases and HPRCT families for allelic duplication at chromosome 7 and 17. We have sequenced the MET tyrosine kinase from germline cells and analysed the copy number and expression of the mutant allele in tumour cells.
Results

Germline mutation of the MET proto-oncogene
Since germline mutations in the MET tyrosine kinase are cosegregated with the tumorigenic phenotype in HPRCT families, we have searched for MET mutation in the germline of the 10 individuals with multiple papillary RCTs included in this series. Forward and reverse sequencing of cDNA of the MET tyrosine kinase and exons 16 ± 19 from genomic DNA revealed base pair substitution A3529G in exon 16 in normal kidney cells of HPRCT family HD104 (Figure 1 ). This nucleotide exchange causes the non conservative amino acid substitution H1112R adjacent to a highly conserved glycine rich region responsible for ATP binding (Hanks and Hunter, 1995) . The A3529G mutation was not detected by direct DNA sequencing and by SSCP analysis of 160 and 320 normal individuals, respectively, implicating that this base substitution is not a polymorphism (L Schmidt, personal communication) . No mutation in exons 16 ± 19 of the MET oncogene was seen in the germline of two aected members (HD783 and HD834) of the other HPRCT family. Of interest, the same base pair substitution A3529G was seen in a`sporadic' case HD835 with multiple bilateral pRCTs. Repeated extraction of normal genomic DNA and sequencing con®rmed the result and disclosed the possibility of carry over during processing for PCR. Normal MET sequences were seen in the germline of the remaining cases.
The mutant allele of the MET gene is duplicated and overexpressed in tumour cells
Previous chromosome analyses showed consequent trisomy of chromosome 7 in sporadic as well as in hereditary papillary RCTs. This ®nding prompted us to investigate whether the mutated allele of MET is duplicated in tumour cells. The mutation resulted in a base substitution at the NlaIII restriction site within exon 16 of the MET in the germline of the HPRCT patient HD104. Therefore, the wild type allele carries a NlaIII site, whereas the mutant allele does not ( Figure  2 ). The PCR ampli®cation of genomic DNA with primers Met6-F and Met6-R and subsequent digestion of the product with NlaIII results in two larger fragments of 103 and 83 bp corresponding to the mutant and wild type allele, respectively. The previous cytogenetic analysis revealed a trisomy of chromosome 7q in tumours HD104B-I (G Kovacs, unpublished data). These tumours showed a higher mutant vs wild type allele (103 vs 83 bp) signal ratio, which indicates the duplication of the mutated allele (Figure 3a) . Tumour HD104A showed a tetrasomy of chromosome 7 in the karyotype and a 103/83 allelic ratio similar to those of normal kidney parenchymal cells indicating that both the wild type and mutated alleles are duplicated.
We have investigated the expression of both the mutated and wild type allele of the MET protooncogene by RT ± PCR in normal and tumour cells from patient HD104. The same digestion approach was used for cDNA as for genomic DNA using another reverse primer Met7-R from exon 17 of the MET tyrosine kinase (Figure 2) . A clearly increased signal ratio (128/108) for the mutated allele was seen in all tumours, with the exception of tumour HD104A (Figure 3b ). Duplication of both wild type and mutant MET alleles resulting in 2 : 2 allelic balance in genomic DNA of tumour HD104A yielded only a slightly higher level of expression of the mutant allele.
Preferential duplication of the same chromosome 7 allele in familial and in some bilateral-multiple tumours
We applied a set of polymorphic microsatellite markers to identify allelic alterations at the short and long arms of chromosome 7 in all sporadic and hereditary papillary RCTs. The results are shown in Table 1 . Consequent duplication of the same chromosome 7q allele was detected in multiple tumours obtained from HPRCT families. Eight tumours (B-I) of case HD104 showed the duplication of allele 1 at locus D7S1824 (7q32-33). The retention of heterozygosity at 7p and duplication of allele 1 at 7q32 in tumour HD104B indicates that selective duplication of the 7q occurred. Each tumour obtained from the two members (HD783 and HD834) of the other HPRCT family showed duplication of the same parental allele at chromosome 7 (Table 1 and Figure 4) . Duplication of the same allele was seen in all but one tumour (D) with allelic imbalance from case HD835 carrying the MET mutation in the germline. Eight tumours from the right kidney and nine from the left kidney were analysed from patient HD833 having no family history of renal cancer. Duplication of the same allele was seen in each tumour showing an allelic imbalance at chromosome 7. Dierent alleles were duplicated at both arms of chromosome 7 in case HD842. In sporadic case HA503 a duplication of dierent alleles at chromosome 7p and/or 7q loci were seen. The same chromosome 7q allele was duplicated in two and three tumours from cases HD793 and FR531, respectively. However, taking into account the low number of tumours analysed, an incidental occurrance of these changes cannot be ruled out. Of interest, duplication of allele 2 at chromosome 7p and retention of heterozygosity without allelic imbalance was seen in case HD832.
Duplication of dierent alleles at chromosome 17q in both familial and sporadic tumours
As a combined trisomy of chromosomes 7 and 17 occurs at early stage of development of papillary RCTs, we have analysed all tumours for allelic status at chromosome 17p and 17q regions. In familial tumours, dierent alleles at chromosome 17p and/or 17q regions were duplicated with exception of HD834 where six times the same allele at chromosome 17p showed an allelic imbalance. Tumours from HD833, HD835, and HD842 also showed duplication of dierent alleles at chromosome 17p and 17q. In cases HA503, HD793 and HD832 when only a few tumours were analysed, imbalance at the same allele was seen. Retention of constitutional heterozygosity at chromosome 17p and over-representation of one allele at chromosome 17q were seen in seven tumours. Retention of 1 : 1 allelic balance at chromosome 17q and allelic imbalance at chromosome 17p was seen in two cases.
Discussion
We have detected a germline mutation in the MET tyrosine kinase in one of the two families with HPRCTs and also found the same mutation in the germline of one of seven individuals with clinically recognized multiple, bilateral papillary RCTs but without family history. The latter case may represent a de novo germ line mutation. The mutant MET allele is duplicated and in comparison to the wild type allele is overexpressed in tumour cells. Cosegregation of germline mutation of the MET with development of multiple papillary RCTs was recently described by Schmidt et al. (1997) in HPRCT families. They have identi®ed missense mutations in the tyrosine kinase domain of the MET proto-oncogene in exons 17 ± 19 in four out of seven hereditary papillary RCT families and also in two individuals with bilateral papillary RCTs. The mutation of the MET receptor tyrosine kinase occurred in only three out of 60 sporadic papillary RCTs. These data strongly implicate the role of constitutive MET activation in the development of multiple papillary RCTs at least in HPRCT families. The MET proto-oncogene encodes a transmembrane tyrosine kinase receptor (Park et al., 1987) for hepatocyte growth factor/scatter factor (HGF/SF), which is capable of exerting morphogenic, mitogenic, motogenic and metastatogenic in¯uences on a wide variety of cells, especially those of epithelial origin (Gherardi and Stoker, 1991; Naldini et al., 1991; Weidner et al., 1993) . The binding of HGF/SF induces dimerisation and autophosphorylation of the MET receptor leading to the initiation of a signalling cascade via activation of the SOS/ras/extracellular kinase dependent (ERK)-signalling pathway (Besser et al., 1997) . The HGF/SF and MET are localized at chromosome 7q21 and 7q31 respectively (Saccone et al., 1992; Dean et al., 1985) . The MET is expressed in most embryonal and also adult tissues and its ubiquitous expression also was shown in dierent types of renal cell carcinomas (Prat et al., 1991) . It was suggested that concomitant expression of the HGF/SF and MET in tumour and/or stromal cells may trigger the growth of renal cell tumours via autocrine or paracrine growth loop (Rong et al., 1993) . The observations made by Schmidt et al. (1997) and also in this study indicate the association between the germline mutation of MET tyrosine kinase and development of multiple papillary RCTs in HPRCT families. Missense mutations in the cytoplasmic domain of MET were seen in both studies which might lead to a constitutive kinase activation without ligand binding or receptor dimerisation.
It is likely that mutation of one allele of the MET does not aect the function of the wild type allele during embryonal morphogenesis and the germline mutation alone is not sucient for initiation of Alleles were designated 1 or 2 and refer to the larger and smaller fragments, respectively. The designation 12 indicates retention of heterozygosity without allelic imbalance, whereas 112 or 122 indicates that either allele 1 or allele 2 is presented in two copies in tumour cells. ND, not determined papillary RCTs. This is indicated by the fact that members of HPRCT families carrying the activating MET mutations in the germline develop normal functioning nephrons. An explanation for multiple tumour development in such families may come from cytogenetic studies, which revealed trisomy of chromosome 7 in up to 10% of normal kidney cells (Kovacs and Brusa, 1989; Emanuel et al., 1992) . There is a forced mitotic activity in developing tissues resulting in variable level of mitotic errors, e.g. in an embryonal genetic noise. A nondisjunction of chromosome 7 results in trisomy in one daughter cell and monosomy in the other one, whereby the segregation of alleles is incidental. We showed in this study, that papillary RCTs in HPRCT families have a duplication of the mutant chromosome 7. This indicates, that papillary RCT will develop only from cells having two copies of the mutant MET allele, whereas cells with duplication of the wild type allele remain`functionally normal'. As none of the HPRCTs shows monosomy of chromosome 7, the loss of the wild type allele does not lead to a growth advantage of such cells. Of interest, the wild type allele is retained and expressed in all analysed papillary RCTs which indicates, that the function of normal MET protein is necessary to maintain integrity of blastemal rest cells and tumour cells as well.
Of particular importance, the HGF/SF via MET receptor mediates dierentiation and organisation of Mardin ± Darly canine kidney cells into branching tubules simulating the early embryonal development of normal nephrons (Montesano et al., 1991) . We suggest that the inherited constitutional activation and duplication of the mutant allele of the MET tyrosine kinase leads to delayed dierentiation of hundreds of the blastemal cells during embryonal development. These cells retain the capacity of proliferation and form embryonal rests growing slowly during life. The ®nding that the development of papillary RCTs is associated with the high number (average 42 per kidney) of such precursor lesions support this hypothesis . When such cells acquire additional somatic alterations, e.g. trisomy of chromosome 17 and others, a tumour may develop. As a duplication of the mutant MET allele is necessary before cells enter the tumorigenic pathway, the chromosomal instability during embryonal development and the number of cells with duplication of the mutant chromosome 7 after birth may have a strong impact on the number of tumours in members of HPRCT families. Schmidt et al. (1997) have diagnosed multiple RCTs in a patient with germline mutation of MET tyrosine kinase, but the patient's mother carrying the same mutation was tumour free at the time of analysis. A low penetrance of the germline mutation in such cases might be explained by this hypothesis.
The lack of germline mutation in two members of another HPRCT family and duplication of the same parental allele of chromosome 7 in multiple tumours suggest that a germline event other than MET tyrosine kinase mutation is involved in the genetics of these tumours. A mutation in the transmembrane or extracellular domain of the MET cannot be excluded in these cases. As the normal MET is ubiquitously expressed in renal parenchymal cells, a concomitant overexpression of the MET ligand HGF/ SF mapped to chromosome 7q22 may also lead to activation and constitutive signal transduction. Inammatory cytokines like IL-1a, TNF-a, TGF-b1 and especially IL-6, which is also mapped to chromosome 7 can upregulate MET expression (Moghul et al., 1994) . These alternative pathways, however, remain to be cleared.
Materials and methods
Tumour samples and DNA extraction
Fresh tissue was obtained from ®ve tumours of the right kidney (HD104A-E) and four tumours of the left kidney (HD104F-I) of HPRCT patient. Paran blocks of tumour Figure 4 Microsatellite analysis of chromosome 7 and 17 in multiple papillary RCTs HD783A-K. Electropherograms indicates duplication of allele 1 at locus D7S817 in all tumours, whereas duplication of dierent alleles was seen at locus D17S969. Tumour DH783J retained the heterozygosity at locus D17S969 without allelic imbalance and normal samples were available from ®ve tumours of the left kidney (HD783A-E) and from six tumours of the right kidney (KD783F-K) of one member and from ®ve tumours of the right kidney (HD834A-E) and two tumours from the left kidney (HD834F, G) of another member of a large Italian HPRCT family. Fresh tumour and normal kidney tissues were available from cases FR503 and FR531, and paran embedded tumour and normal tissues were obtained for the rest of the cases, all without history of familial cancer. Bilateral tumours occurred in sporadic cases HD832, HD833, HD842, HD835 and HA531, tumours from both kidneys were available for analysis from HD833, HD835 and HA531. Histological diagnosis was established according to the Heidelberg Classi®cation system . Analysis of tumour DNA without or with minimal contamination of normal nucleic acid is a critical step to determine a correct allelic status especially duplication of alleles by means of microsatellite assay. When available, DNA was extracted from short term cultures of papillary RCTs and normal kidney tissues as described previously (Bugert and Kovacs, 1996) . Alternatively, one H&E stained slide was used to identify tumour areas free of stromal and in¯ammatory cells, which were then microdissected from corresponding unstained paran slides. DNA was isolated from deparanized and rehydrated tissue fragments after digestion with proteinase K overnight at 558C and phenol/chloroform extraction followed by ethanol precipitation. The concentration of each sample was adjusted to 10 ng/ml and 5 ml (50 ng) were used as a template in 10 ml reactions.
Mutation analysis of the MET tyrosine kinase
Sequencing of the MET tyrosine kinase domain ampli®ed by RT ± PCR was performed when RNA was available. Reverse transcription of the RNA isolated from normal kidney tissues was performed by using oligo dT primers and Superscript II reverse transcriptase according to the supplier's instructions (Gibco ± BRL, Eggenstein, Germany). PCR conditions were as follows: 2 min at 958C and 30 s at 958C, 30 s at 608C, 30 s at 728C for 30 cycles with a delayed last step for 10 min at 728C using the primers Met3-F (5'-TCATAGGAAGAGGGCATTTTGGTT-3') and Met3-R (5'-GAGTTTGCAGACTTTCCAAAGCC-3'). PCR products were puri®ed with a Qiagen kit and cloned with the pGEM-T-system (Promega, Madison). Plasmid DNA was sequenced with the fmol cycle sequencing kit (Promega, Madison) with cyanine (Cy5) labelled M13-universal and M13-reverse primers under the following cycling conditions: 958C for 2 min, then 958C for 30 s, 428C for 30 s, 708C for 1 min for 30 cycles. From genomic DNA exons 16 ± 19 of the MET oncogene were ampli®ed by the corresponding primers for each exon ; sequences were kindly provided by Laura Schmidt). For sequencing, the PCR products were reampli®ed with nested forward primers tailed with universal sequencing primer sites. The nucleotide sequences of these primers are the following.
Exon 16-uni:
5'-TGTAAAACGACGGCCAGTTACGCAGTGCTAACCAAG-3' Exon 17-uni:
5'-TGTAAAACGACGGCCAGTTCCATAATGAAGTTAATGTC-3' Exon 18-uni:
5'-TGTAAAACGGCCAGTAGATGCTTAGTTTATGCTTTTC-3' Exon 19-uni:
5'-TGTAAAACGACGGCCAGTATTTCAGCCACGGGTAATAA-3'
The ampli®ed MET exons were directly sequenced with Cy5-labelled primers using the Thermosequenase cycle sequencing kit (Amersham Buchler, Braunschweig) following the manufacturers advertisements. The labelled products of the sequencing reaction were visualized in digitalized form using the ALFexpress system (Pharmacia, Freiburg). Nucleotide and deduced amino acid sequences were analysed with the HUSAR/GCG software package (German Cancer Research Center; Heidelberg).
Establishing the copy number and level of expression of the mutant met allele
The mutation A3529G in exon 16 changes a recognition site for the restriction endonuclease NlaIII (GATC) in cases HD104 and HD835 and could therefore be used to distinguish between mutated and wild type alleles. We used primers Met6-F (5'-GGCATTTTGGTTGTGTTATATC-3') and Met6-R (5'-GGTTAAATAAAATGCCACTTAC-3') to amplify a 103 bp fragment from genomic DNA (Figure 1 ). For analysis of expression of the mutated and wild type alleles a 128 bp fragment of the cDNA was ampli®ed with primers Met6-F and Met7-R (5'-GATTCCCTCGGTCAGAAAATT-3'). The Met7-R binds to the next exon 17 and therefore, ampli®cation of contaminating chromosomal DNA could be excluded. Aliquots of each sample were digested with NlaIII, and the resulting fragments were separated on a 4% NuSieve 3 : 1 Agarosegel (FMC, Rockland, USA) in TBE. The gels were stained with ethidium bromide. Both experiments were repeated three times.
Microsatellite analysis
The following polymorphic microsatellite markers mapped to chromosomes 7 and 17 were used in this study: D7S817 (7p15), D7S1801 (7q21-31), D7S796 (7q22-31), D7S2847 (7q31), D7S1820 (7q31-33), D7S1824 (7q32-33), D17S969 (17p11-12), D17S1537 (17p11-12), D17S1298 (17p13), D17S1306 (17q11-12), D17S1299 (17q12). Primers were supplied either by Pharmacia Biotech (Freiburg, Germany) or MWG Biotech (Ebersberg, Germany). DNA amplification was carried out in 96 well polycarbonate plates using a PTC 100 Thermocycler (MJ Research Inc., Watertown Massachusetts). The reactions were performed in a total volume of 10 ml with 50 ng genomic DNA, 50 mM KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , 0.5% Tween 20, 0.01% Bovine Serum Albumine, 200 mM dNTPs, 2 pMol of each primer and 0.5 U Taq-Polymerase (Promega, Madison). All forward primers were labelled at the 5' end with Cy5 for¯uorescence detection. After 2 min of denaturation at 948C the samples were subjected to the following ampli®cation program: 948C for 30 s, 558C for 40 s, and 728C for 30 s for 28 cycles with a delayed last step of 10 min at 728C. After adding 20 ml of stop solution (100% deionized formamide with 50 mM EDTA and 5 mg/ml DextranBlue 2000), adding Cy5-labelled PCR products as size markers and heating all samples to 948C, 2 ± 10 ml of the PCR product were separated on a 5% denaturing polyacrylamide gel (Readymix ALFgrade, Pharmacia Biotech) or Hydrolink Long Ranger (Biozym, Hess. Oldendorf) at 400 V, 55 mA and 35 W for 90 ± 120 min. Analysis was performed on an automated DNA sequencer (ALFexpress, Pharmacia Biotech). The¯uorescence dye was directly detected by a laser and the collected data were calculated by using the Fragment Manager (FM 1.2) software (Pharmacia Biotech).
